Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Mutations in SCN1A gene cause genetic epilepsies and familial migraine.
• These mutations lead to increased persistent current in Na(V) 1.1 channels, altering neuronal excitability.
• Understanding this biophysical defect is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate ranolazine's ability to selectively inhibit increased persistent current in mutant Na(V) 1.1 channels.
• To assess ranolazine's efficacy against Na(V) 1.1 channel mutations associated with specific neurological disorders.

Main Methods:

• Heterologous expression of wild-type (WT) and mutant Na(V) 1.1 channels in tsA201 cells.
• Whole-cell patch clamp recording to evaluate tonic and use-dependent ranolazine block.
• Assessment of ranolazine's effect on current density, activation, inactivation, and recovery from inactivation.

Main Results:

• Ranolazine selectively blocked persistent current in mutant Na(V) 1.1 channels with significant selectivity over tonic and use-dependent peak current block.
• This selective inhibition was observed for mutations linked to generalized epilepsy with febrile seizures plus, severe myoclonic epilepsy of infancy, and familial hemiplegic migraine type 3.
• Achievable brain concentrations of ranolazine suppressed channel activation in cells expressing mutant channels.

Conclusions:

• Selective suppression of increased persistent current by ranolazine is a feasible therapeutic strategy.
• Ranolazine shows potential for treating familial neurological disorders caused by specific sodium channel mutations.
• Targeting channel biophysical defects offers a novel approach for neurological disease treatment.